Pharmaceutical care for patients with breast and ovarian cancer

Liekweg, Andrea; Westfeld, Martina; Braun, Michael; Zivanovic, Oliver; Schink, Tania; Kuhn, Walther; Jaehde, Ulrich

doi:10.1007/s00520-012-1385-z

Cited by 43 publications

(59 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…After reviewing the titles and abstracts, 617 records were excluded because they did not include a study of pharmacist interventions in adult patients with cancer; did not assess the impact of interventions; or included non‐ambulatory patients. The remaining 40 records were selected for full‐text examination, of which 11 met all the eligibility criteria and were included in this systematic review . The excluded studies and the reasons for their exclusion are detailed in Appendix 2.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

The effects of pharmacist interventions on adult outpatients with cancer: A systematic review

et al. 2017

View full text Add to dashboard Cite

SummaryWhat is known and objectives: Most antineoplastic drugs are highly toxic and have low therapeutic indexes, which can result in drug-related problems. In this context, pharmacist interventions may play an important role in the success of the treatment.The objective of this study was to examine the effects of pharmacist interventions on adult outpatients with cancer using antineoplastic drugs. Methods:A literature search was performed using PubMed, ISI Web of Science and LILACS databases from January 1990 to April 2016, using MeSH terms or text words related to pharmacist interventions, cancer and outpatient care. Studies published in English, Portuguese or Spanish on the effects of pharmacist interventions in outcome measures in adult outpatients with cancer were included. Two independent authors performed study selection and data extraction with a consensus process. The articles were analysed according to previously established criteria, such as country, study design, setting, population, type of cancer, description of the intervention and control groups, outcomes, main conclusions and study limitations. Results and discussion:A total of 874 records were identified, of which 11 satisfied the inclusion criteria. The studies were conducted mainly in the United States and included patients aged >50 years. Most studies had a before-after design. Pharmacist interventions primarily included educating and counselling patients on the management of adverse events. Rates of nausea and vomiting control, medication adherence and patient satisfaction were the most common outcome measures; a significant benefit in these parameters as a result of pharmacist interventions was noted in most studies. What is new and conclusion:The findings from this systematic review indicate that pharmacist interventions can improve outcome measures in outpatients with cancer.However, the collective quality of the studies was poor and gaps identified indicate that further research is needed to provide more robust results. K E Y W O R D Scancer, pharmaceutical care, pharmacists, systematic review

show abstract

Section: Resultsmentioning

confidence: 99%

“…All studies were published in English and reported between 2012 and 2016. Sample size ranged from 12 to 249 individuals, with most studies including sample sizes smaller than 100 individuals (n=7) . In most studies (n=10), the mean age of patients was >50 years, and an equal proportion of men and women was recruited.…”

Section: Resultsmentioning

confidence: 99%

The effects of pharmacist interventions on adult outpatients with cancer: A systematic review

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Studies have shown that a clinical pharmacist involved in a multidisciplinary treatment team applying IMM, may identify a high number of DRPs 8–10. Previous studies have demonstrated that clinical pharmacists can improve supportive treatment for pain and gastrointestinal disturbance among cancer patients 11 12. Cytotoxic, biological and immune system-modulating drugs caused 31% of the fatal adverse events reported to the Norwegian Medicines Agency in 2011 13.…”

Section: Introductionmentioning

confidence: 99%

Pharmacist assessment of drug-related problems on an oncology ward

Cehajic¹,

Bergan

Bjordal

2015

Eur J Hosp Pharm

View full text Add to dashboard Cite

Objectives Cancer patients have a high incidence of concurrent chronic diseases, the pharmacological treatment of which is generally complex and carries an inherent risk of drug-related problems (DRPs). DRPs can interfere with the patient's health outcomes. No systematic investigation of the prevalence of DRPs in hospitalised cancer patients has been performed in Norway. The aim of this study was to characterise the DRPs on an oncology ward, using systematic medication review, and to suggest interventions to optimise drug therapy. Methods A clinical pharmacist applying the integrated medicines management method reviewed the drug treatment of 48 in-patients. The identified DRPs and the interventions proposed by the clinical pharmacist were discussed with the oncologists and oncology nurses, and the conclusions were characterised. Results 100 DRPs were identified through medication review. Of these, 41% were identified in the medication charts, 21% by evaluating the choice of drug and 21% by evaluating drug dosing. 75% of the suggested interventions for DRPs were implemented in the drug therapy of the patients.Conclusions The results of this study demonstrate that the suggested interventions for reducing DRPs were frequently implemented by oncologists. The results also demonstrate that a clinical pharmacist, using medication review on an oncology ward, probably can improve the quality of the drug treatment of hospitalised cancer patients. BACKGROUND

show abstract

“…The symptom-based quality-of-life questionnaires were administered before the first and after the third course of chemotherapy 10. The questionnaires were: Functional Assessment of Cancer Therapy-General (FACT-G), Functional Assessment of Chronic Illness Therapy-Diarrhoea (FACIT-D), Functional Assessment of Cancer Therapy-Anaemia (FACT-AN), Functional Assessment of Cancer Therapy-Neurotoxicity (FACT-GOG-NTX).…”

Section: Methodsmentioning

confidence: 99%

Role of clinical oncology pharmacist in determination of pharmaceutical care needs in patients with colorectal cancer

et al. 2017

View full text Add to dashboard Cite

ObjectiveTo determine and evaluate the pharmaceutical care needs and quality of life of patients with colorectal cancer.Methods36 Patients with colorectal cancer eligible for chemotherapy after surgery were included in the study. The patients were followed up during 3 courses of chemotherapy and individual pharmaceutical care plans were developed. The quality of life of patients was evaluated before and after the third course of chemotherapy.ResultsThe incidence of drug-related problems (DRPs) in chemotherapy-treated patients was reduced in the 3rd course as compared with 1st course (63.9% vs 75%, respectively; n=36; p>0.05). The clinical oncology pharmacist gave 147 recommendations to patients, which were followed in 98% (n=144) of cases. 91.7% (n=132) of the recommendations of clinical oncology pharmacists solved the drug-related problems; however, the remaining 8.3% (n=12) did not solve the problems and the patients were referred to a doctor for further investigations. The symptom-related quality of life of patients related to anaemia, diarrhoea and neurotoxicity was reduced after the third course of chemotherapy (p<0.05).ConclusionsThe pharmaceutical care provided by the clinical oncology pharmacist has an important role in the identification and resolution of DRPs. Evaluation of symptom-related quality of life is important for the monitoring of patients receiving chemotherapy.

show abstract

Pharmaceutical care for patients with breast and ovarian cancer

Cited by 43 publications

References 31 publications

The effects of pharmacist interventions on adult outpatients with cancer: A systematic review

The effects of pharmacist interventions on adult outpatients with cancer: A systematic review

Pharmacist assessment of drug-related problems on an oncology ward

Role of clinical oncology pharmacist in determination of pharmaceutical care needs in patients with colorectal cancer

Contact Info

Product

Resources

About